AcelRx Pharma (NASDAQ: ACRX) reported Q4 EPS of ($0.18), $0.02 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $511 thousand versus the consensus estimate of $1.51 million.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.